Abstract FLT3 mutations occur in approximately 25% of all acute myeloid leukemia (AML) patients. While several FLT3 inhibitors have received FDA approval. their use is currently limited to combination therapies with chemotherapy. as resistance occurs. https://parisnaturalfoodes.shop/product-category/chlorella/